- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05734430
Genetics of Appendix Cancer Study (GAP)
April 29, 2024 updated by: Andreana Holowatyj, PhD, MSCI
Genetics of Appendix Cancer: The GAP Study
The GAP Study is a prospective cohort study designed to comprehensively investigate genetic variations that may contribute to cancer development among individuals diagnosed with appendix/appendiceal cancer who are ages 18+ years.
Study Overview
Status
Recruiting
Conditions
- Appendix Cancer
- Appendiceal Neoplasms
- Appendix Adenocarcinoma
- Appendiceal Cancer
- Appendiceal Adenocarcinoma
- Appendix Tumor
- Appendiceal Mucinous Neoplasm
- Appendiceal Carcinoid Tumor
- Appendiceal Neoplasm Malignant Secondary
- Appendix Mucinous Neoplasm
- Appendix Cancer Metastatic
- Appendix NET
- Low-Grade Appendix Mucinous Neoplasm
- High Grade Appendix Mucinous Neoplasm
- High Grade Appendix Mucinous Adenocarcinoma
Intervention / Treatment
Detailed Description
The Genetics of Appendix Cancer (GAP) Study aims to analyze hereditary factors, tumor characteristics and clinical features/outcomes among adults diagnosed with appendix cancer and their biological parents.
Patients are recruited at any time after a diagnosis of appendix cancer and followed for up to 6 years after study enrollment.
This cohort is enriched by robust biospecimens and data collections.
Study Type
Observational
Enrollment (Estimated)
700
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: GAP Study Coordinator (Rebecca B.)
- Phone Number: 615-936-8544
- Email: gapcancerstudy@vumc.org
Study Locations
-
-
Tennessee
-
Nashville, Tennessee, United States, 37232
- Recruiting
- Vanderbilt-Ingram Cancer Center
-
Principal Investigator:
- Andreana N Holowatyj, PhD, MSCI
-
Contact:
- GAP Study Coordinator (Rebecca B.)
- Phone Number: 615-936-8544
- Email: gapcancerstudy@vumc.org
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
Yes
Sampling Method
Non-Probability Sample
Study Population
Individuals age 18+ years diagnosed with appendix cancer, and biological parents of study participants.
Description
Inclusion Criteria:
GAP Social
- Known diagnosis of appendix cancer in the United States
- Mentally and physically able to consent and participate in the study
GAP Vanderbilt
- Known diagnosis of appendix cancer
- Diagnosed by and/or consulting with a physician/clinical provider participating in the GAP Study
- Mentally and physically able to consent and participate in the study
GAP Parent
- Biological parents (mother and/or father) of individuals actively participating in the GAP Study
- Residing in the United States
- Mentally and physically able to consent and participate in the study
Exclusion Criteria:
- Women pregnant at the time of consent
- Prisoners
- Unable to provide informed consent
- Unable to read, write, or complete questionnaires in English
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
GAP Social
Individuals ages 18+ years with an appendix cancer diagnosis in the United States.
|
Whole exome sequencing
Collection of archived fixed-formalin, paraffin-embedded (FFPE) primary appendix tumor tissues that were previously removed
|
GAP Vanderbilt
Individuals ages 18+ years with an appendix cancer diagnosis seen at Vanderbilt.
|
Whole exome sequencing
Collection of archived fixed-formalin, paraffin-embedded (FFPE) primary appendix tumor tissues that were previously removed
|
GAP Parent
Biological parents of active GAP (Social and Vanderbilt) Study participants.
|
Whole exome sequencing
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Prevalence and spectrum of pathogenic and likely pathogenic germline variants in appendix cancer patients and their biological parents
Time Frame: Within 6 years of study enrollment
|
Within 6 years of study enrollment
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Association of germline genetic variants with clinical, pathologic and molecular features of appendix tumors
Time Frame: Within 6 years of study enrollment
|
Within 6 years of study enrollment
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Andreana N Holowatyj, PhD, MSCI, Vanderbilt-Ingram Cancer Center
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Helpful Links
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
November 11, 2022
Primary Completion (Estimated)
November 1, 2032
Study Completion (Estimated)
November 1, 2034
Study Registration Dates
First Submitted
February 8, 2023
First Submitted That Met QC Criteria
February 8, 2023
First Posted (Actual)
February 21, 2023
Study Record Updates
Last Update Posted (Actual)
May 1, 2024
Last Update Submitted That Met QC Criteria
April 29, 2024
Last Verified
April 1, 2024
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Digestive System Diseases
- Neoplasms by Histologic Type
- Neoplasms by Site
- Carcinoma
- Neoplasms, Glandular and Epithelial
- Gastrointestinal Neoplasms
- Digestive System Neoplasms
- Gastrointestinal Diseases
- Neuroectodermal Tumors
- Neoplasms, Germ Cell and Embryonal
- Neoplasms, Nerve Tissue
- Intestinal Diseases
- Intestinal Neoplasms
- Neuroendocrine Tumors
- Cecal Diseases
- Cecal Neoplasms
- Neoplasms
- Adenocarcinoma
- Cystadenocarcinoma
- Adenocarcinoma, Mucinous
- Carcinoid Tumor
- Neoplasms, Cystic, Mucinous, and Serous
- Appendiceal Neoplasms
Other Study ID Numbers
- VICC GI 2280
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Appendix Cancer
-
Turku University HospitalOulu University Hospital; Kuopio University Hospital; Seinajoki Central Hospital and other collaboratorsNot yet recruitingAppendicitis | Appendix Cancer | Appendix Mass | Appendix Abscess | Appendix Nec | Appendix Tumor | Appendix Diseases
-
Hanyang UniversityCompletedAppendix, UltrasonographyKorea, Republic of
-
Zhongshan Hospital Xiamen UniversityActive, not recruitingColonoscopy | Gastrointestinal Microbiome | Appendix | Carbon Dioxide InsufflationChina
-
Laval UniversityCiusss de L'Est de l'Île de MontréalRecruitingColorectal Cancer | Peritoneal Carcinomatosis | Peritoneal Metastases | Appendix Cancer | Appendix NeoplasmCanada
-
Saglik Bilimleri UniversitesiNot yet recruitingPediatric ALL | Appendix DiseasesTurkey
-
Hillel Yaffe Medical CenterUnknown
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)CompletedPrimary Peritoneal Cavity Cancer | Carcinoma of the AppendixUnited States
-
Wake Forest University Health SciencesBoehringer IngelheimTerminated
-
City of Hope Medical CenterNational Cancer Institute (NCI)RecruitingPeritoneal Carcinomatosis | Stage IV Uterine Corpus Cancer AJCC v8 | Stage IVA Uterine Corpus Cancer AJCC v8 | Stage IVB Uterine Corpus Cancer AJCC v8 | Metastatic Malignant Solid Neoplasm | Malignant Uterine Neoplasm | Clinical Stage IV Gastric Cancer AJCC v8 | Metastatic Colorectal Carcinoma | Stage... and other conditionsUnited States
-
Dartmouth-Hitchcock Medical CenterCompletedGastric Cancer | Colorectal Cancer | Esophageal Cancer | Small Bowel Cancer | Appendix Cancer | Ampullary CancerUnited States
Clinical Trials on Genetic profiling
-
Avera McKennan Hospital & University Health CenterWithdrawnMetastatic Breast Cancer | Breast Tumor | Advanced Gynecologic CancerUnited States
-
University of DundeeBritish Lung Foundation; Newcastle University; University of Leicester; University... and other collaboratorsActive, not recruitingIdiopathic Pulmonary Fibrosis | Lung Diseases, Interstitial | Idiopathic Interstitial Pneumonias | Alveolitis, Extrinsic Allergic | Lung; Disease, Interstitial, With Fibrosis | Bird Fancier's LungUnited Kingdom
-
Centre Hospitalier Universitaire de NīmesInstitut National de la Santé Et de la Recherche Médicale, FranceCompletedDiabetic Foot | Staphylococcus AureusFrance
-
Institute of Cancer Research, United KingdomActive, not recruiting
-
Karolinska InstitutetActive, not recruitingChronic Atrophic GastritisSweden
-
AnchorDx Medical Co., Ltd.The First Affiliated Hospital with Nanjing Medical University; Peking University... and other collaboratorsCompletedBladder Cancer | Urothelial CarcinomaChina
-
Institute of Cancer Research, United KingdomActive, not recruitingProstate CancerUnited Kingdom
-
University Health Network, TorontoActive, not recruitingCarcinoma, Pancreatic DuctalCanada
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveBelgium
-
National Cancer Institute (NCI)CompletedProstate CancerUnited States